Cargando…

Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery

BACKGROUND: The purpose of this study was to investigate the ocular bacterial flora in patients scheduled to undergo cataract surgery and compare the antibacterial effects of besifloxacin ophthalmic suspension 0.6% and moxifloxacin ophthalmic solution 0.5% in these patients. METHODS: This was a pros...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bucci, Frank A, Evans, Ruth E, Amico, Loretta M, Morris, Timothy W, Fluet, Angel T, Sanfilippo, Christine M, DeCory, Heleen H, Comstock, Timothy L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435077/ https://www.ncbi.nlm.nih.gov/pubmed/25999691 http://dx.doi.org/10.2147/OPTH.S83162

Ejemplares similares

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
por: Silverstein, Bruce E, et al.
Publicado: (2012)

Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates
por: Sanfilippo, Christine M., et al.
Publicado: (2017)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
por: Morris, Timothy W, et al.
Publicado: (2011)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
por: Haas, Wolfgang, et al.
Publicado: (2011)

Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%
por: Blondeau, Joseph M, et al.
Publicado: (2021)

Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6%
por: DeCory, Heleen H., et al.
Publicado: (2020)

Pharmacokinetics and aqueous humor penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing cataract surgery
por: Bucci, Frank A, et al.
Publicado: (2016)

Safety of Besifloxacin Ophthalmic Suspension 0.6% in Cataract and LASIK Surgery Patients
por: Majmudar, Parag A., et al.
Publicado: (2014)

Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration
por: Torkildsen, Gail, et al.
Publicado: (2010)

In Vitro Time-Kill of Common Ocular Pathogens with Besifloxacin Alone and in Combination with Benzalkonium Chloride
por: Blondeau, Joseph, et al.
Publicado: (2021)

Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study
por: Malhotra, Ranjan, et al.
Publicado: (2012)

An Evaluation of Staphylococci from Ocular Surface Infections Treated Empirically with Topical Besifloxacin: Antibiotic Resistance, Molecular Characteristics, and Clinical Outcomes
por: Schechter, Barry A., et al.
Publicado: (2019)

The Safety of Besifloxacin Ophthalmic Suspension 0.6 % Used Three Times Daily for 7 Days in the Treatment of Bacterial Conjunctivitis
por: Malhotra, Ranjan, et al.
Publicado: (2013)

Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop
por: Coffey, Martin J, et al.
Publicado: (2013)

An assessment of the tolerability of moxifloxacin 0.5% compared to azithromycin 1.0% in DuraSite(®)
por: Granet, David, et al.
Publicado: (2007)

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
por: Nielsen, Steven A, et al.
Publicado: (2013)

Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
por: Comstock, Timothy L, et al.
Publicado: (2010)

Advances in Corticosteroid Therapy for Ocular Inflammation: Loteprednol Etabonate
por: Comstock, Timothy L., et al.
Publicado: (2012)

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients [Corrigendum]
Publicado: (2013)

Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones
por: Haas, Wolfgang, et al.
Publicado: (2013)

Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery
por: Comstock, Timothy L, et al.
Publicado: (2011)

Penetration of 0.3% ciprofloxacin, 0.3% ofloxacin, and 0.5% moxifloxacin into the cornea and aqueous humor of enucleated human eyes
por: Silva, G.C.M., et al.
Publicado: (2017)

Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies
por: Fong, Raymond, et al.
Publicado: (2019)

Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae
por: Haas, Wolfgang, et al.
Publicado: (2010)

A Case Report of Severe Corneal Toxicity following 0.5% Topical Moxifloxacin Use
por: Vignesh, A.P., et al.
Publicado: (2015)

Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections
por: Mah, Francis S., et al.
Publicado: (2016)

Comparison of the frequency of use of a pupil expansion device with and without an intracameral phenylephrine and ketorolac injection 1%/0.3% at the time of routine cataract surgery
por: Bucci, Frank A, et al.
Publicado: (2017)

Studies of the Room-Temperature Multiferroic Pb(Fe(0.5)Ta(0.5))(0.4)(Zr(0.53)Ti(0.47))(0.6)O(3): Resonant Ultrasound Spectroscopy, Dielectric, and Magnetic Phenomena
por: Schiemer, J, et al.
Publicado: (2014)

The Effect of Niobium Doping on the Electrical Properties of 0.4(Bi(0.5)K(0.5))TiO(3)-0.6BiFeO(3) Lead-Free Piezoelectric Ceramics
por: Fisher, John G., et al.
Publicado: (2015)

Microstructural Design of Ba(0.5)La(0.5)Co(0.5)Fe(0.5)O(3) Perovskite Ceramics
por: Gierszewska, Daria, et al.
Publicado: (2021)

Exchange bias effect in polycrystalline Bi(0.5)Sr(0.5)Fe(0.5)Cr(0.5)O(3) bulk
por: Li, S. Z., et al.
Publicado: (2023)

Magnetoelastic interactions and magnetic damping in Co(2)Fe(0.4)Mn(0.6)Si and Co(2)FeGa(0.5)Ge(0.5) Heusler alloys thin films for spintronic applications
por: Chumak, O. M., et al.
Publicado: (2021)

Structural Insight into La(0.5)Ca(0.5)Mn(0.5)Co(0.5)O(3) Decomposition in the Methane Combustion Process
por: Nikolaeva, Olga, et al.
Publicado: (2021)

Crystal chemistry and compressibility of Fe(0.5)Mg(0.5)Al(0.5)Si(0.5)O(3) and FeMg(0.5)Si(0.5)O(3) silicate perovskites at pressures up to 95 GPa
por: Koemets, Iuliia, et al.
Publicado: (2023)

Investigation of annealing effects on the physical properties of Ni(0.6)Zn(0.4)Fe(1.5)Al(0.5)O(4) ferrite
por: Lahouli, R., et al.
Publicado: (2019)

Interfacial interaction driven enhancement in the colossal magnetoresistance property of ultra-thin heterostructure of Pr(0.6)Sr(0.4)MnO(3) in proximity with Pr(0.5)Ca(0.5)MnO(3)
por: Gayathri, V., et al.
Publicado: (2023)

Safety of intracameral injection of levofloxacin 0.5% eye drops single dose 0.6 ml preservative free on rabbit eye
por: Edwar, Lukman, et al.
Publicado: (2023)

Near-infrared emitting CdTe(0.5)Se(0.5)/Cd(0.5)Zn(0.5)S quantum dots: synthesis and bright luminescence
por: Yang, Ping, et al.
Publicado: (2012)

The Effect of Topical Cyclosporine 0.05% on Dry Eye after Cataract Surgery
por: Chung, Yeon Woong, et al.
Publicado: (2013)

Unravelling the nature of magneto-electric coupling in room temperature multiferroic particulate (PbFe(0.5)Nb(0.5)O(3))–(Co(0.6)Zn(0.4)Fe(1.7)Mn(0.3)O(4)) composites
por: Bhoi, Krishnamayee, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jl1mo5io0vsq0dgvnurs4m6she